Companies: 10,795·Total market cap: $144.5T
BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc.

BCRXNASDAQHealthcare● Active
$8.43
+$0.02(+0.24%)
Market Cap$1.8B
P/E Ratio—
52W High$11.23
52W Low$6
SEC Filings

BioCryst Pharmaceuticals, Inc. (BCRX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0000882796 · BCRX · NASDAQ · as of Jun 8, 2026

Filing snapshot

1,000+
Total Filings
4
Latest Form
2026-06-02
Most Recent
1994
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0000882796 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-26
Fiscal Year End
Feb 26, 2026
Accession No.
0001628280-26-012240
Primary Document
bcrx-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0000882796 · Accession 0001628280-26-012240

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-06
View 10-Q on SEC
8-KCurrent Report
FORM 8-K
2026-05-06Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-05-12
View
10-QQuarterly Report
10-Q
2026-05-06
View
8-KCurrent Report
FORM 8-K
2026-05-06
View
8-KCurrent Report
FORM 8-K
2026-05-04
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-04-29
View
ARSARS
ARS
2026-04-23
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-23
View
DEF 14AProxy Statement
DEF 14A
2026-04-23
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-04-07
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
10-KAnnual Report
10-K
2026-02-26
View
8-KCurrent Report
FORM 8-K
2026-02-26
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-12
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-02-09
View
3Initial Statement of Beneficial Ownership
Initial Statement of Beneficial Ownership
2026-01-27
View
Showing 1–15 of 495 filingsForm 4 / 144 hidden· 1000 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0000882796  |  Exchange: NASDAQ · Healthcare

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has submitted 1,000+ documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 1994. As a Healthcare sector company with CIK 0000882796, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is BioCryst Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent BioCryst Pharmaceuticals, Inc. 10-K was filed on 2026-02-26 for fiscal year ending 2026. Historical BCRX 10-K annual reports are available from 2016 through 2026.

Investors researching BioCryst Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
SYRE SEC Filings →PHVS SEC Filings →TRVI SEC Filings →STOK SEC Filings →ZYME SEC Filings →NTLA SEC Filings →ARDX SEC Filings →MAZE SEC Filings →
→ BCRX Financials→ BCRX Earnings→ BCRX Insider Trades

Frequently Asked Questions

BCRX SEC Filings · 8 questions

BioCryst Pharmaceuticals, Inc. (BCRX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 1,000+ filings and access original documents at no cost. BioCryst Pharmaceuticals, Inc.'s CIK is 0000882796.

BCRX SEC filingsBioCryst Pharmaceuticals, Inc. SEC documentsfind BCRX 10-K